Evidence map›Paper›PMID 29084200›Full record

ArticleBone marrow transplantation2018

'Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

L Giaccone, G Mancini, N Mordini, G Gargiulo, V De Cecco, S Angelini, M Arpinati, D Baronciani, V Bozzoli, S Bramanti and 29 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors at 20 institutions in 1 country.

L GiacconeDepartment of Molecular Biotechnology and Health Sciences, University of Torino, and Department of Oncology, AOU Città della Salute e della Scienza di Torino, Torino, Italy.
G ManciniDivision of Hematology, Azienda Ospedaliera Universitaria Ospedali Riuniti, Ancona, Italy.
N MordiniDivision of Hematology, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy.
G GargiuloUOC Ematology and TCSE, AOU Federico II, Napoli, Italy.
V De CeccoUOC Oncoematology Pediatrica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
S AngeliniDivision of Hematology and Stem Cell Transplantation, Ospedale Mazzoni, Ascoli Piceno, Italy.
M ArpinatiDivision of Hematology, University Hospital Sant'Orsola-Malpighi, Bologna, Italy.
D BaroncianiOspedale di Riferimento Regionale Businco, AO Brotzu, Cagliari, Italy.
V BozzoliDivisione di Ematologia, Ospedale di Lecce, Lecce, Italy.
S BramantiDivision of Hematology, Ospedale Humanitas, Rozzano, Italy.
E CaloreDepartment of Women's and Children's Health, Clinic of Pediatric Hemato-Oncology, University Hospital of Padova, Padova, Italy.
I M CavattoniHematology and Bone Marrow Transplant Unit, Ospedale Centrale di Bolzano, Bolzano, Italy.
M CimminielloUOC di Ematologia con TMO, Ospedale San Carlo, Potenza, Italy.
A A ColomboDivisione di Ematologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
L FacchiniHematology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy.
S FalcioniU.O.C. Ematologia e Trapianto di Cellule Staminali Emopoietiche, Ospedale Mazzoni, Ascoli Piceno, Italy.
M FaraciDepartment of Pediatric Hematology-Oncology, IRCCS G. Gaslini, Genova, Italy.ORCID 0000-0001-5715-501X
R FedeleHematology and Stem Cell Transplant Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy.
S GuidiDepartment of Hematology, Bone Marrow Transplant Unit, University of Firenze, Firenze, Italy.
A P IoriDepartment of 'Cellular Biotechnologies and Hematology', Azienda Policlinico Umberto I, Università La Sapienza, Roma, Italy.
S MarottaUOC Ematology and TCSE, AOU Federico II, Napoli, Italy.
M C MicòHematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
G MiloneHematology and Bone Marrow Transplant Unit, Azienda Policlinico Vittorio Emanuele, Catania, Italy.ORCID 0000-0002-7840-4414
F OnidaHematology-BMT Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico-University of Milan, Milano, Italy.ORCID 0000-0002-2991-3474
D PastoreDipartimento di Ematologia, Università di Bari, Bari, Italy.
F PatriarcaAzienda Ospedaliera-Universitaria di Udine, DISM Università di Udine, Udine, Italy.
M PiniHematology, AO SS Antonio e Biagio e C Arrigo, Alessandria, Italy.
R RaimondiHematology and Bone Marrow Transplant Unit, Ospedale San Bortolo, Vicenza, Italy.
A RovelliBMT Unit, MBBM Foundation, Paediatric Department, University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy.
S SantaroneUnità Terapia Intensiva Ematologica per il Trapianto Emopoietico, Ospedale Civile, Pescara, Italy.
A SeverinoDivisione di Ematologia, Ospedale San Camillo, Roma, Italy.
C SkertUnit of Blood Disease and Stem Cell Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, AO Spedali Civili di Brescia, Brescia, Italy.
M T L StanghelliniMolecular Hematology Laboratory, IRCCS San Raffaele Scientific Institute, Milano, Italy.
C TecchioDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.
E VassalloPediatric Onco-Hematology and Stem Cell Transplant Division, AO Città della Salute e della Scienza di Torino, Torino, Italy.
M ChiarucciDivision of Hematology, Azienda Ospedaliera Universitaria Ospedali Riuniti, Ancona, Italy.
B BrunoDepartment of Molecular Biotechnology and Health Sciences, University of Torino, and Department of Oncology, AOU Città della Salute e della Scienza di Torino, Torino, Italy.
F BonifaziDivision of Hematology, University Hospital Sant'Orsola-Malpighi, Bologna, Italy.ORCID 0000-0003-1544-9911
A OlivieriDivision of Hematology, Azienda Ospedaliera Universitaria Ospedali Riuniti, Ancona, Italy.
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITAzienda Ospedaliero Universitaria Ospedali Riuniti · ITFederico II University Hospital · ITIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · ITPoliclinico San Matteo Fondazione · ITAzienda ospedaliera "Bianchi-Melacrino-Morelli" · ITAzienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo · ITAzienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele · ITAzienda Sanitaria Ospedaliera S.Croce e Carle Cuneo · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITIstituto Giannina Gaslini · ITIstituto Nazionale di Fisica Nucleare, Sezione di Lecce · ITOspedale di Bolzano · ITOspedale generale di zona San Camillo Treviso · ITOspedale Maggiore · ITOspedale Papa Giovanni XXIII · ITOspedale San Bortolo · ITOspedale San Carlo · ITPoliclinico Umberto I · ITRegione Puglia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several guidelines have been published about management of chronic GvHD (cGvHD), but the clinical practice still remains demanding. The Gruppo Italiano Trapianto di Midollo Osseo (GITMO) has planned a prospective observational study on cGvHD, supported by a dedicated software, including the updated recommendations. In view of this study, two surveys have been conducted, focusing the management of cGvHD and ancillary therapy in cGvHD, to address the current 'real life' situation. The two surveys were sent to all 57 GITMO centers, performing allografting in Italy; the response rate was 57% and 66% of the interviewed centers, respectively. The first survey showed a great disparity especially regarding steroid-refractory cGvHD, although extracorporeal photo-apheresis resulted as the most indicated treatment in this setting. Another challenging issue was the strategy for tapering steroid: our survey showed a great variance, and this disagreement could be a real bias in evaluating outcomes in prospective studies. As for the second survey, the results suggest that the ancillary treatments are not standardized in many centers. All responding centers reported a strong need to standardize management of cGvHD and to participate in prospective trials. Before starting observational and/or interventional studies, a detailed knowledge of current practice should be encouraged.

Indexed as

Chronic DiseaseFemaleGraft vs Host DiseaseHumansItalyMale

Identifiers

PMID29084200
OpenAlexW2766289481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.